Antineo : Breast metastatic adenocarcinoma tumour model – MDA-MD-231
-
MDA-MD-231 cells
Human MDA-MD-231 cells were isolated from the pleural effusion of a patient with metastatic triple negative breast adenocarcinoma.
-
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing MDA-MD-231 tumours can be treated by intra-peritoneal, intra-venous, intratumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the MDA-MD-231 cells as xenograft Mean ± SEM (n=5; take rate 100%)
Antineo can also implant this model orthotopically.
-
Standard-Of-Care Drug Reponses
Figure 2: (View PDF)
Effect of taxol treatment on MDA-MD-231 tumour growth Mean ± SEM (n=4 per group; take rate 100%)
A MDA-MD-231 GFP +, with a high metastasis propensions developed in vivo is available at Antineo (model ID MDA-MD-231 GFP).